Reproductive Health Matters - Hormonal contraception and risk of HIV acquisition: Uganda and Zimbabwe
January 12th, 2009This study among 6,109 HIV-negative women recruited from family planning clinics who were using either Depo Provera or combined oral contraception in Uganda and Zimbabwe tested the women quarterly for HIV over 15-24 months. 213 women became HIV positive during the study. Neither hormonal contraceptive method was associ…
Business Wire - Pharmacia and Upjohn Will Appeal Verdict in Simon Case, ‘Ruling is Not Supported by the Evidence’
January 9th, 2009 NEW YORK — Pfizer said its subsidiary, Pharmacia and Upjohn, will appeal today’s jury verdict linking its product, Provera, with plaintiff Merle Simon’s breast cancer. The case, Simon vs. Wyeth, et al., was heard in the Philadelphia Court of Common Pleas.
“While we have great sympathy for what Mrs. Simon and her family have been through, today’s verdict is neither supported by the evidence introduced during the trial …
British Plastics & Rubber - Cut costs by extruding wider rolls.(film & sheet production)
January 8th, 2009A COEXTRUSION cast line for stretch film 5 metres wide with up to seven layers has been demonstrated by Adtech Provera of Italy.
Related Results
Depo-Provera/NorplantDepo-Provera: the quarterly contraceptiveDepo-Provera approved by FDAComparing Norplant and Depo-ProveraFIA slams Provera over Cyp…
OB/GYN News - Bone loss related to Depo-Provera reverses after discontinuing therapy
January 4th, 2009 Bone loss associated with depot medroxyprogesterone acetate was reversible in a prospective population-based cohort study.
In 183 nonpregnant, reproductive-age users of the injectable contraceptive, which is sold as Depo-Provera, bone density at the spine changed at an annualized mean rate of -0.87%, comp…
Resources for Feminist Research - "Depo-Provera: Does this Contraceptive Choice Support the Health and Well-Being of Adolescents and Young Women?
December 28th, 2008Wershler, Laura. “Depo-Provera: Does this Contraceptive Choice Support the Health and Well-Being of Adolescents and Young Women?” Canadian Woman Studies/ les cahiers de la femme. Special Issue: Women’s Health and Well-Being, vol. 24, no. 1 (Fall 2004), pp. 105-107.
Related Results
Depo-Provera/Norpla…
Internal Medicine News - Chronic Depo-Provera linked to heart disease risk in small study
December 25th, 2008 Chronic use of depot medroxyprogesterone acetate may have an adverse effect on cardiovascular health, a small, nonrandomized study suggests.
The widely used, long-acting contraceptive sold as Depo-Provera and given as a 150-mg injection every 12 weeks inhibits ovarian follicle proliferation. This causes anovulati…
Reproductive Health Matters - Improving contraceptive delivery to women with HIV: Kenya
December 23rd, 2008319 pregnant women with HIV participating in a perinatal HIV transmission study were referred to local clinics for contraceptive counselling and management and followed prospectively. Median time to sexual activity post-partum was two months. 72% (231) initiated hormonal contraceptive use at about three months post-partum (range 1-11 months) and used it for at least two months du…
Food Trade Review - Griffith Laboratories launches BBQ food flavours.(Products)
December 18th, 2008In Anne Walch’s article, “Hormones and Menopause Revisited” Jun/July 04, the paragraph beginning “Premarin, also known as conjugated equilin estrogen (CEE) …” should have read: “Premarin, also known as conjugated equilin estrogen (CEE), is derived from pregnant mare’s urine. The estrogens in Premarin are perfect for a menopausal mare, but foreign to a human female. The same goes fo…
Reproductive Health Matters - Hormonal contraception and risk of HIV acquisition: Uganda and Zimbabwe.(ROUND UP: HIV/AIDS)(Clinical report)
December 15th, 2008This study among 6,109 HIV-negative women recruited from family planning clinics who were using either Depo Provera or combined oral contraception in Uganda and Zimbabwe tested the women quarterly for HIV over 15-24 months. 213 women became HIV positive during the study. Neither hormonal contraceptive method was …
Most Popular
13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
5 Regular Mistakes In Public Speaking
…
Business Wire - Statement from Attorney James Morris of Brent Coon & Associates Regarding Jury’s Verdict in the Case of Simon Vs. Wyeth Et Al
December 11th, 2008PHILADELPHIA — “Once again, we have proven that postmenopausal hormone therapy causes breast cancer,” said attorney James A. Morris of the firm Brent Coon & Associates, commenting on the latest verdict in the nationwide hormone replacement therapy litigation. A Philadelphia jury found Pfizer Inc. (NYSE: PFE) liable for failing to properly warn New Jersey plaintiff Merle Simon’s physicians of the breast cancer risk posed by Provera, the progestin half of hormone replacement therapy. Pfiz…

